文献速递头颈与中枢神经肿瘤

吞咽优化调强放疗对比标准调强放疗治疗头颈癌患者(DARS):一项3期、多中心、随机、对照试验

Dysphagia-optimised intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in patients with head and neck cancer (DARS): a phase 3, multicentre, randomised, controlled trial.
PubMed 文献 · Lancet Oncol · 2023-07-06

DARS是一项在爱尔兰和英国22个放疗中心开展的3期随机对照试验,纳入112例口咽或下咽癌患者,比较吞咽优化调强放疗(DO-IMRT)与标准调强放疗。结果显示DO-IMRT组12个月MDADI综合评分显著高于标准IMRT组(77.7 vs 70.6,均差7.2,95%CI 0.4-13.9,p=0.037)。作者认为DO-IMRT改善患者报告的吞咽功能,应考虑作为咽癌放疗的新标准治疗。

要点

  • DO-IMRT组12个月MDADI综合评分显著高于标准IMRT组,均差7.2(95%CI 0.4-13.9,p=0.037)。
  • 最常见3-4级晚期不良事件为听力受损、口干和吞咽困难,两组间数值不同。
  • 作者认为DO-IMRT应考虑作为咽癌放疗的新标准治疗。

核心结论

  • 作者认为,与标准IMRT相比,DO-IMRT改善了患者报告的吞咽功能,应考虑作为咽癌放疗的新标准治疗。

研究设计与样本

  • DARS为平行组、3期、多中心、随机、对照试验,在爱尔兰和英国的22个放疗中心开展。
  • 纳入年龄≥18岁、T1-4 N0-3 M0口咽或下咽癌、WHO体力状态评分0或1、无既存吞咽功能障碍的患者。
  • 采用最小化算法中央随机(1:1)分配至DO-IMRT或标准IMRT,平衡因素包括中心、化疗使用、肿瘤类型、美国癌症联合委员会肿瘤分期。
  • 患者和言语治疗师对治疗分配设盲;放疗30次、6周完成,原发和淋巴结肿瘤剂量65 Gy,其余咽亚部位和微观病变风险淋巴结区剂量54 Gy。
  • DO-IMRT组对位于高剂量靶区外的上、中咽缩肌或下咽缩肌体积实行强制性50 Gy平均剂量约束。

主要发现

  • 2016年6月24日至2018年4月27日共登记118例患者,其中112例被随机分配(每组56例);女性22例(20%),男性90例(80%),中位年龄57岁(IQR 52-62)。
  • 中位随访39.5个月(IQR 37.8-50.0)。
  • DO-IMRT组12个月MDADI综合评分显著高于标准IMRT组(平均77.7 [SD 16.1] vs 70.6 [17.3];均差7.2 [95%CI 0.4-13.9];p=0.037)。
  • 23例患者报告25起严重不良事件:16起评估为与研究治疗无关(DO-IMRT组9起 vs 标准IMRT组7起),9起为严重不良反应(DO-IMRT组2起 vs 标准IMRT组7起)。
  • 最常见3-4级晚期不良事件:听力受损DO-IMRT组9/55(16%) vs 标准IMRT组7/55(13%),口干3/55(5%) vs 8/55(15%),吞咽困难3/55(5%) vs 8/55(15%);无治疗相关死亡。

临床怎么用

  • 作者认为DO-IMRT应考虑作为接受放疗的咽癌患者的新标准治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Most newly diagnosed oropharyngeal and hypopharyngeal cancers are treated with chemoradiotherapy with curative intent but at the consequence of adverse effects on quality of life. We aimed to investigate if dysphagia-optimised intensity-modulated radiotherapy (DO-IMRT) reduced radiation dose to the dysphagia and aspiration related structures and improved swallowing function compared with standard IMRT. METHODS: DARS was a parallel-group, phase 3, multicentre, randomised, controlled trial done in 22 radiotherapy centres in Ireland and the UK. Participants were aged 18 years and older, had T1-4, N0-3, M0 oropharyngeal or hypopharyngeal cancer, a WHO performance status of 0 or 1, and no pre-existing swallowing dysfunction. Participants were centrally randomly assigned (1:1) using a minimisation algorithm (balancing factors: centre, chemotherapy use, tumour type, American Joint Committee on Cancer tumour stage) to receive DO-IMRT or standard IMRT. Participants and speech language therapists were masked to treatment allocation. Radiotherapy was given in 30 fractions over 6 weeks. Dose was 65 Gy to primary and nodal tumour and 54 Gy to remaining pharyngeal subsite and nodal areas at risk of microscopic disease. For DO-IMRT, the volume of the superior and middle pharyngeal constrictor muscle or inferior pharyngeal constrictor muscle lying outside the high-dose target volume had a mandatory 50 Gy mean dose constraint. The primary endpoint was MD Anderson Dysphagia Inventory (MDADI) composite score 12 months after radiotherapy, analysed in the modified intention-to-treat population that included only patients who completed a 12-month assessment; safety was assessed in all randomly assigned patients who received at least one fraction of radiotherapy. The study is registered with the ISRCTN registry, ISRCTN25458988, and is complete. FINDINGS: From June 24, 2016, to April 27, 2018, 118 patients were registered, 112 of whom were randomly assigned (56 to each treatment group). 22 (20%) participants were female and 90 (80%) were male; median age was 57 years (IQR 52-62). Median follow-up was 39·5 months (IQR 37·8-50·0). Patients in the DO-IMRT group had significantly higher MDADI composite scores at 12 months than patients in the standard IMRT group (mean score 77·7 [SD 16·1] vs 70·6 [17·3]; mean difference 7·2 [95% CI 0·4-13·9]; p=0·037). 25 serious adverse events (16 serious adverse events assessed as unrelated to study treatment [nine in the DO-IMRT group and seven in the standard IMRT group] and nine serious adverse reactions [two vs seven]) were reported in 23 patients. The most common grade 3-4 late adverse events were hearing impairment (nine [16%] of 55 in the DO-IMRT group vs seven [13%] of 55 in the standard IMRT group), dry mouth (three [5%] vs eight [15%]), and dysphagia (three [5%] vs eight [15%]). There were no treatment-related deaths. INTERPRETATION: Our findings suggest that DO-IMRT improves patient-reported swallowing function compared with standard IMRT. DO-IMRT should be considered a new standard of care for patients receiving radiotherapy for pharyngeal cancers. FUNDING: Cancer Research UK.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Nutting C, Finneran L, Roe J, et al. Dysphagia-optimised intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in patients with head and neck cancer (DARS): a phase 3, multicentre, randomised, controlled trial. Lancet Oncol. 2023. PMID: 37423227. doi:10.1016/S1470-2045(23)00265-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。